The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Immunopathology of secondary‐progressive multiple sclerosis
Abstract
Twenty‐three plaques obtained at early autopsy from 2 patients with secondary‐progressive multiple sclerosis were examined immunohistochemically for microglia/macrophages, and for immunoglobulins and components of activated complement. Most of the lesions examined in both cases exhibited evidence of low‐grade active demyelination of an unusual type (frustrated phagocytosis) in periplaque white matter. This included linear groups of microglia engaging short segments of disrupted myelin that were associated with deposits of C3d, an opsonin formed during complement activation. Similar microglia/C3d/myelin profiles were not observed in newly forming lesions in cases of acute multiple sclerosis or other central white matter diseases. As C3d coupling is known to increase the immunogenicity of potential antigens enormously, present findings point to disrupted myelin close to plaques as a possible source of the putative multiple sclerosis antigen. Ongoing myelin destruction found in a high proportion of old, established plaques was surprising. It suggests that slowly expanding lesions (progressive plaques), in which ongoing myelin breakdown occurs in the absence of florid perivascular cell cuffing or other histological signs of acute inflammation, contribute to disease progression in cases of secondary‐progressive multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
The Instructive Role of Innate Immunity in the Acquired Immune Response
Fearon, D. T., & Locksley, R. M. (1996) · Science · doi:10.1126/science.272.5258.50 · Cited by 1,719
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Complement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Linington, C., Bradl, M., Lassmann, H., Brunner, C., & Vass, K. (1988) · PubMed · Cited by 708
Microglia in degenerative neurological disease
McGeer, P. L., Kawamata, T., Walker, D. G., Akiyama, H., Tooyama, I., & McGeer, E. G. (1993) · Glia · doi:10.1002/glia.440070114 · Cited by 596
Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574
Self-citationT. Griffin, W. S., Sheng, J. G., Roberts, G. W., & Mrak, R. E. (1995) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199503000-00014 · Cited by 549
Monocyte/macrophage differentiation in early multiple sclerosis lesions
Brück, W., Porada, P., Poser, S., Rieckmann, P., Hanefeld, F., Kretzschmarch, H. A., & Lassmann, H. (1995) · Annals of Neurology · doi:10.1002/ana.410380514 · Cited by 530
Cited by
Dobson, R., & Giovannoni, G. (2019) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,148
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Pathological mechanisms in progressive multiple sclerosis
Mahad, D. H., Trapp, B. D., & Lassmann, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70256-x · Cited by 1,137
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Lassmann, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028936 · Cited by 937
Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684
“For commercial re-use, please contact journals.permissions@oup.com 1987; Ferguson et al., 1997; Prineas et al., 2001), but an understanding of the functional phenotype and origin of these cells in different stages of lesion formation is limited (Bogie et al., 2014).”
BackgroundAn updated histological classification system for multiple sclerosis lesions
Kuhlmann, T., Ludwin, S., Prat, A., Antel, J., Brück, W., & Lassmann, H. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1653-y · Cited by 692
Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
Dal-Bianco, A., Grabner, G., Kronnerwetter, C., Weber, M., Höftberger, R., Berger, T., Auff, E., Leutmezer, F., Trattnig, S., Lassmann, H., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1636-z · Cited by 463
Veerhuis, R., Nielsen, H. M., & Tenner, A. J. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.003 · Cited by 419
Pathology of Demyelinating Diseases
Popescu, B. F. G., & Lucchinetti, C. F. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132443 · Cited by 397
Complement in neurological disorders and emerging complement-targeted therapeutics
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0400-0 · Cited by 363
Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla
Bagnato, F., Hametner, S., Yao, B., van Gelderen, P., Merkle, H., Cantor, F. K., Lassmann, H., & Duyn, J. H. (2011) · Brain · doi:10.1093/brain/awr278 · Cited by 351
Homogeneity of active demyelinating lesions in established multiple sclerosis
Breij, E. C. W., Brink, B. P., Veerhuis, R., van den Berg, C., Vloet, R., Yan, R., Dijkstra, C. D., van der Valk, P., & Bö, L. (2008) · Annals of Neurology · doi:10.1002/ana.21311 · Cited by 353
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging
Haacke, E. M., Makki, M., Ge, Y., Maheshwari, M., Sehgal, V., Hu, J., Selvan, M., Wu, Z., Latif, Z., Xuan, Y., et al. (2009) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21676 · Cited by 329
Demyelination versus remyelination in progressive multiple sclerosis
Bramow, S., Frischer, J. M., Lassmann, H., Koch-Henriksen, N., Lucchinetti, C. F., Sørensen, P. S., & Laursen, H. (2010) · Brain · doi:10.1093/brain/awq250 · Cited by 319
Remyelination can be extensive in multiple sclerosis despite a long disease course
Patani, R., Balaratnam, M., Vora, A., & Reynolds, R. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00805.x · Cited by 318
Pathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Secondary progressive multiple sclerosis: current knowledge and future challenges
Rovaris, M., Confavreux, C., Furlan, R., Kappos, L., Comi, G., & Filippi, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70410-0 · Cited by 303
Onset of secondary progressive phase and long-term evolution of multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P. A., & Ebers, G. C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304333 · Cited by 291
Peruzzotti-Jametti, L., Bernstock, J. D., Vicario, N., Costa, A. S. H., Kwok, C. K., Leonardi, T., Booty, L. M., Bicci, I., Balzarotti, B., Volpe, G., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.01.020 · Cited by 285
Hammond, K. E., Metcalf, M., Carvajal, L., Okuda, D. T., Srinivasan, R., Vigneron, D., Nelson, S. J., & Pelletier, D. (2008) · Annals of Neurology · doi:10.1002/ana.21582 · Cited by 286
Inflammation, demyelination, and degeneration — Recent insights from MS pathology
Stadelmann, C., Wegner, C., & Brück, W. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.007 · Cited by 276
Neuroinflammation across neurological diseases
Shi, F.-D., & Yong, V. W. (2025) · Science · doi:10.1126/science.adx0043 · Cited by 274
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Pathology of Multiple Sclerosis: Where Do We Stand?
Popescu, B. F. G., Pirko, I., & Lucchinetti, C. F. (2013) · Continuum · doi:10.1212/01.con.0000433291.23091.65 · Cited by 261
Interleukin‐1β promotes oligodendrocyte death through glutamate excitotoxicity
Takahashi, J. L., Giuliani, F., Power, C., Imai, Y., & Yong, V. W. (2003) · Annals of Neurology · doi:10.1002/ana.10519 · Cited by 256
Detecting axon damage in spinal cord from a mouse model of multiple sclerosis
Kim, J. H., Budde, M. D., Liang, H.-F., Klein, R. S., Russell, J. H., Cross, A. H., & Song, S.-K. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.09.009 · Cited by 235
Zirngibl, M., Assinck, P., Sizov, A., Caprariello, A. V., & Plemel, J. R. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00538-8 · Cited by 270
Pathology and disease mechanisms in different stages of multiple sclerosis
Lassmann, H. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.05.010 · Cited by 224
Elliott, C., Wolinsky, J. S., Hauser, S. L., Kappos, L., Barkhof, F., Bernasconi, C., Wei, W., Belachew, S., & Arnold, D. L. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518814117 · Cited by 217
Kaunzner, U. W., Kang, Y., Zhang, S., Morris, E., Yao, Y., Pandya, S., Hurtado Rua, S. M., Park, C., Gillen, K. M., Nguyen, T. D., et al. (2019) · Brain · doi:10.1093/brain/awy296 · Cited by 199
Mechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191
Brink, B. P., Veerhuis, R., Breij, E. C. W., van der Valk, P., Dijkstra, C. D., & Bö, L. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.147 · Cited by 191
The role of microglia in multiple sclerosis
Luo, C., Jian, C., Liao, Y., Huang, Q., Wu, Y., Liu, X., Zou, D., & Wu, Y. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s140634 · Cited by 187
Microglia in multiple sclerosis: protectors turn destroyers
Yong, V. W. (2022) · Neuron · doi:10.1016/j.neuron.2022.06.023 · Cited by 185
Rissanen, E., Tuisku, J., Rokka, J., Paavilainen, T., Parkkola, R., Rinne, J. O., & Airas, L. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131698 · Cited by 171
Preactive lesions in multiple sclerosis
van der Valk, P., & Amor, S. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832b4c76 · Cited by 156
Oligodendrocytes and the early multiple sclerosis lesion
Prineas, J. W., & Parratt, J. D. E. (2012) · Annals of Neurology · doi:10.1002/ana.23634 · Cited by 149
Self-citationRegulation of myelination by microglia
Santos, E. N., & Fields, R. D. (2021) · Science Advances · doi:10.1126/sciadv.abk1131 · Cited by 137
Chronic inflammation in multiple sclerosis - seeing what was always there
Matthews, P. M. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0240-y · Cited by 128
Dulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
Singh, S., Dallenga, T., Winkler, A., Roemer, S., Maruschak, B., Siebert, H., Brück, W., & Stadelmann, C. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0831-8 · Cited by 118
Tallantyre, E. C., Bo, L., Al-Rawashdeh, O., Owens, T., Polman, C. H., Lowe, J., & Evangelou, N. (2009) · Brain · doi:10.1093/brain/awp106 · Cited by 93
Hendrickx, D. A. E., Koning, N., Schuurman, K. G., Strien, M. E. V., Eden, C. G. V., Hamann, J., & Huitinga, I. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31827fd9e8 · Cited by 72
Reduction of microglial activity in a model of multiple sclerosis by dipyridamole
Sloka, S., Metz, L. M., Hader, W., Starreveld, Y., & Yong, V. W. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-89 · Cited by 53
“Given these observations and that activated macrophage/microglia are present in high and persistent amounts in the CNS of patients with MS [1,2], a medication that suppresses microglia or normalizes its activity in MS could be a useful therapy.”
BackgroundMicroglia in multiple sclerosis - pathogenesis and imaging
Airas, L., & Yong, V. W. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001045 · Cited by 52
Microglia suppress the secondary progression of autoimmune encephalomyelitis
Tanabe, S., Saitoh, S., Miyajima, H., Itokazu, T., & Yamashita, T. (2019) · Glia · doi:10.1002/glia.23640 · Cited by 52
Nylund, M., Sucksdorff, M., Matilainen, M., Polvinen, E., Tuisku, J., & Airas, L. (2022) · Brain Communications · doi:10.1093/braincomms/fcab301 · Cited by 48
TSPO-detectable chronic active lesions predict disease progression in multiple sclerosis
Polvinen, E., Matilainen, M., Nylund, M., Sucksdorff, M., & Airas, L. M. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200133 · Cited by 36
Slowly eroding lesions in multiple sclerosis
Sethi, V., Nair, G., Absinta, M., Sati, P., Venkataraman, A., Ohayon, J., Wu, T., Yang, K., Shea, C., Dewey, B. E., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458516655403 · Cited by 34
“We modeled the parameters taking into account both expansion at the lesion boundary (proportional to radius or volume of lesion or at a fixed rate over time; supplement equations (2)–(4)) and resorption (either as a function of LV or at a fixed rate over time; supplement equations (5) and (6)).”
MethodMicroglia subtypes in acute, subacute, and chronic multiple sclerosis
Prineas, J. W., & Lee, S. (2023) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlad046 · Cited by 16
Self-citationChia, S.-Y., Li, M., Li, Z., Tu, H., Lee, J. W. L., Qiu, L., Ling, J., Reynolds, R., Albani, S., Tan, E.-K., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01519-4 · Cited by 15
Metabolic control of microglia
Garcia-Segura, M. E., Pluchino, S., & Peruzzotti-Jametti, L. (2024) · Advances in Neurobiology · doi:10.1007/978-3-031-55529-9_34 · Cited by 4
Insights and challenges on animal models for progressive multiple sclerosis
Nalepa, I. F., Haahr, N. O., Bekiaris, V., Jakobsen, M. R., Asuni, A. A., & Benmamar-Badel, A. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03805-3 · Cited by 1
“These lesions are defined by an inactive demyelinated core with few or no infiltrating cells, surrounded by a rim of chronically activated microglia [28, 63].”
Metadata
- Authors
- Prineas, J. W., Kwon, E. E., Cho, E., Sharer, L. R., Barnett, M. H., Oleszak, E. L., Hoffman, B., & Morgan, B. P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2001-10-05
- Volume
- 50
- Issue
- 5
- Pages
- 646-657
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2059218087
- Cited by
- 453
- References
- 66
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.